Analysts think NTLA stock price could increase by 562%
Apr 07, 2025, 11:25 AM
9.28%
What does NTLA do
Intellia Therapeutics, based in Cambridge, Massachusetts, develops CRISPR/Cas9-based therapeutics for high unmet medical needs, including treatments for ATTR amyloidosis and hereditary angioedema. The company went public on May 6, 2016.
26 analysts think NTLA stock price will increase by 561.54%. The current median analyst target is $43.86 compared to a current stock price of $6.63. The lowest analysts target is $9.09 and the highest analyst target is $111.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
